USOR 24310 - Ph1/1b single agent in combo with an androgen receptor in patients with prostate

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer

Disease Types: Prostate

Available at: Arlington Heights, Chicago Resurrection, Niles